Clinical trialNCT06549465RecruitingPhase 2Interventional

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

SponsorConvergent TherapeuticsEnrollment60PSMA PET-Positive Castration-Resistant Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California San Diego
San Diego, California, United States
Rana McKay, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Praful Ravi, MB, BChir, MRCP
Recruiting
Washington University in St. Louis
St Louis, Missouri, United States
Vikas Prasad, MD, PhD
Recruiting
X Cancer Omaha / Urology Cancer Center
Omaha, Nebraska, United States
Luke Nordquist, MD
Recruiting
Laura & Isaac Perlmutter Cancer Center
New York, New York, United States
David Wise, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Anis Hamid, MD
Recruiting
New York Presbyterian/weill Cornell Medical Center
New York, New York, United States
Cora Sternberg, MD
Recruiting
Duke University Medical Center
Durham, North Carolina, United States
Daniel George, MD
Recruiting
the Cleveland Clinic Foundation
Cleveland, Ohio, United States
Shilpa Gupta, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

45 kBq55 kBq60 kBqIn-111 rosopatamab tetraxetan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Aug 2024
Primary completion: 31 Dec 2025
Completion: 30 Apr 2027
Last update posted: 24 Aug 2025
Registered enrollment: 60
Registry id: NCT06549465

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.